Strategic Allocation Framework

Rosa Canet-Avilés, PhD Vice President, Scientific Programs & Education CIRM ICOC Meeting March 28, 2024



CIRM Transformation Is at the Heart of CIRM's Mission

OUR MISSION

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world







Advance World Class Science

- Develop shared resources
- Build knowledge networks



Deliver Real World Solutions

- Advance therapies to marketing approval
- Create a manufacturing partnership network
- Expand Alpha Clinics Network
- Create Community Care Centers of Excellence

Provide Opportunity for All

- Build a diverse and highly skilled workforce
- Deliver a roadmap for access and affordability

The Strategic Allocation Framework (SAF) is a structured and data-driven approach to prioritize resource allocation and provide recommendations for continued implementation of CIRM's strategic plan



CIRM needs to strategically allocate remaining resources to maximize its impact by considering available funds and reviewing past allocations

- CIRM has established itself as a leader in stem cell and regenerative medicine, funding basic research, infrastructure, education/training, and regenerative medicine discovery and clinical development
- Since CIRM's inception, the regenerative medicine field has grown exponentially
- CIRM has finite resources
- Demand for CIRM funding exceeds available resources
- Science Subcommittee (Sept '23) Prioritization Kickoff Discussion (BM Fischer-Colbrie)
 - Next Steps: Ask for CIRM staff to develop an approach and recommendations for prioritization

Over the past few months, CIRM has developed a framework to provide strategic recommendations for funding allocation



The Strategic Allocation Framework (SAF) is a structured and data-driven approach to prioritize resource allocation and provide recommendations for continued implementation of CIRM's strategic plan



Structure

- Background & Rationale
 - Remaining Funds
 - Regenerative Medicine Landscape
- CIRM's Impact to Date
- Strategic Allocation Framework
- Proposed Timeline



Output

Recommendations for strategic priorities



Total Research Budget

From Prop 71 & Prop 14





Current Research Allocation


Excluding expended/scheduled payments & approved allocations

Remaining Balance: **\$3.54B**

- For Neuro Research: **\$1.11B**
- Access & Affordability: \$93.56M

CIRM Regenerative Medicine Landscape

Exponential growth in the number of stem cell and genetic therapies companies, products, academic faculty, research projects and clinical trials from 2005 to 2022



The regenerative medicine field is expanding rapidly, increasing the need for strategic allocation in funding

Sources: Alliance for Regenerative Medicine (ARM) Annual Data Report (2022); American Society of Gene & Cell Therapy (ASGCT) Quarterly Report, Q2, (2021)



CIRM's Impact:



Development of Cell and Gene Therapies

CIRM is committed to advancing cell and gene therapies from research to FDA marketing approval, while supporting patient access and scaling of manufacturing processes



Collaborative Networks for Discovery Research

CIRM is fostering collaborative ecosystems that leverage CIRM's investments, enhancing understanding of disease mechanisms and leading to discoveries that will push boundaries in treatment development



Training and Workforce Development

CIRM's educational initiatives integrate education with practical applications, creating a comprehensive network that connects training with real-world application and leverages CIRM-funded infrastructure



Advancements in Regenerative Medicine Technologies

CIRM supports research to improve regenerative medicine technologies ensuring the continuous evolution of the field

Recommendations will determine the impact of CIRM moving forward







Determine:

How can CIRM make the greatest impact on its mission?

How might CIRM effectively allocate its remaining budget of \$3.54B?



